Dr Reddy's Resolves Legacy Issues At Duvvada After FDA Clears Plant
Dr Reddy’s has been given the all-clear for its Indian formulations manufacturing facility in Duvvada, Visakhapatnam, after the FDA issued an EIR closing out an inspection at the plant that has suffered longstanding quality issues.
You may also be interested in...
Sterling Pharma Solutions completes an expansion of its UK pilot plant facility, Aphena invests, Dr Reddy’s and Asymchem get nods from the FDA, Ampersand Capital Partners acquires Germany’s Vibalogics, and Xellia strikes a deal with Civica Rx.
Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.